The effects of alpha-2 adrenoceptor antagonist, atipamezole, on spatial learning in scopolamine-treated and aged rats.
In order to study whether noradrenergic drugs improve age-related cognitive dysfunctions the present experiments investigated whether atipamezole, a selective and specific alpha-2 antagonist, improves spatial learning impairment due to cholinergic blockade (scopolamine 0.8 mg/kg) or aging in rats. Previously, it has been shown that atipamezole dose-dependently (0.03-3.0 mg/kg) increases the turnover of noradrenaline in rat brain. According to the present results, atipamezole (0.1, 0.3, 0.6 mg/kg) did not affect spatial learning/memory when assessed in a free swim trial of the water maze task in control rats. Furthermore, atipamezole (0.1, 0.6 mg/kg) did not improve learning deficit in scopolamine treated young rats. Higher doses (greater than or equal to 1.0 mg/kg) of atipamezole could not be tested, because they induce floating behaviour in rats. In aged rats, which were screened to be impaired in the initial acquisition of the water maze task, 0.3 mg/kg atipamezole impaired further learning of this task. Because previous studies suggest that age-related learning impairment in the water maze may be, at least partly, due to a cholinergic deficit, the present results suggest that atipamezole which increases the release of noradrenaline in brain does not alleviate this learning deficit.
Department of Neurology, University of Kuopio, Finland.
J
J
Sirviö
P
P
Riekkinen
E
E
MacDonald
M
M
Airaksinen
R
R
Lammintausta
P J
PJ
Riekkinen
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000375:Aging / Q000502:physiology / Q000523:psychology*; D000818:Animals; D007093:Imidazoles / Q000627:therapeutic use*; D007859:Learning Disabilities / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D008125:Locus Coeruleus / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D008569:Memory Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D018727:Muscarinic Antagonists; D051381:Rats; D012601:Scopolamine / Q000633:toxicity*; D013037:Spatial Behavior; D013550:Swimming
D000317:Adrenergic alpha-Antagonists; D007093:Imidazoles; D018727:Muscarinic Antagonists; C050701:atipamezole; D012601:Scopolamine